Addex TherapeuticsADXN
13F holders, Q4 2025 (December 31)5holders +1
1new positions
0sold out
$7.72avg. 13F price*
At the end of Q4 2025, 5 institutions reported holding Addex Therapeutics Ltd. (ADXN) in their 13F filings, up 1 from Q3 2025. 1 opened new positions and 0 sold out. The largest holders were Morgan Stanley ($2K), UBS Group AG ($1K) and GAMMA Investing LLC ($625).
- Company
- Addex Therapeutics Ltd.
- CUSIP
- 00654J206
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q3 2025 → Q4 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 1 | $2K |
| Exits | 0 | $0 |
All 13F filers, Q3 2025 → Q4 2025: 455 shares bought and 44 shares sold, net +411 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 5 holders
| Morgan Stanley | 0.00% | New | 300 | $2K |
| UBS Group AG | 0.00% | Add +15500.0% | 156 | $1K |
| GAMMA Investing LLC | 0.00% | Reduce -33.1% | 81 | $625 |
| Rhumbline Advisers | 0.00% | No change | 72 | $554 |
| SBI Securities Co., Ltd. | 0.00% | Reduce -80.0% | 1 | $8 |
"% of holder's portfolio" is ADXN's weight in each manager's 13F, not the share of Addex Therapeutics Ltd. the manager owns.